ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1004

Cost-Effectiveness Analysis Of Two Rituximab Based Therapeutic Regimens For Longstanding Rheumatoid Arthritis

Luca Quartuccio1, Rossella Di Bidino2, Matteo Ruggeri3, Domenico Biasi4, Franco Schiavon5, Leonardo Punzi6, Silvano Adami7, Americo Cicchetti3 and Salvatore De Vita8, 1Rheumatology Clinic, DSMB, University of Udine, Udine, Italy, 2HTA Unit, “A.Gemelli” Teaching Hospital, Rome, Italy, 3Faculty of Economics, Catholic University of the Sacred Heart, Rome, Italy, 4Rheumatology Clinic, University of Verona, Verona, Italy, 5Rheumatology Clinic, University of Padova, Padova, Italy, 6University of Padova, Rheumatology Unit, Padova, Italy, 7Rheumatology Department, University of Verona, Verona, Italy, 8Rheumatology, DSMB, University Hospital Santa Maria della Misericordia, Udine, Italy

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Economics, rheumatoid arthritis (RA) and rituximab

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Epidemiology and Health Services II & III

Session Type: Abstract Submissions (ACR)

Background/Purpose: socioeconomic costs of rheumatoid arthritis (RA) are very high. Biologic therapies with different biologic targets are now available for moderate to severe RA, and these drugs increased the overall direct costs of RA. Thus, therapeutic strategies to improve the cost-effectiveness of the biologics are welcome. Rituximab (RTX) is generally administered intravenously 1 g x 2 (day 1- day 15, regimen 1) and the retreatment is scheduled at the time of clinical relapse. A more intensive regimen has been proposed: 1 g x 2 (day 1- day 15, regimen 2) every six months, following  the “treat to target” approach (1). The aim of this study is to compare the cost-effectiveness of two regimens of RTX administration in longstanding RA patients.

Methods: an observational retrospective study was conducted in three Centers. One hundred and two patients suffering from moderate to severe longstanding RA (disease duration more than two years) were enrolled. 47 followed regimen 1, while 55 patients were treated with regimen 2. All the patients were followed for at least one year. A cost effectiveness analysis (CEA) based on a Markov Model were conducted on the basis of sample data collected and scientific literature. Markov Model represented natural evolution of RA and was composed by four states: Treatment, Response, Relapse, and Death. An hypothetical cohort of 300.000 populated the model and was followed till death adopting a societal perspective. Pharmaceutical, direct health, and indirect costs were estimated as well as health quality. Univariate and probabilistic sensitivity analysis (PSA) were done. CEA was conducted for the whole sample of patients and for a subgroup of  them (those with rheumatoid factor and/or anti-cyclic citrullinated peptide).

Results: results for the overall sample show at 10-20-30 year that regimen 1 is less costly and associated with an higher QoL compared to regimen 2. PSA at 10 years estimated a probability of 94.20%  for regimen 1 to be cost-effective given a willingness to pay of 30000 € /QALY. The subanalysis in seropositive patients showed that regimen 1 is more cost-effectiveness than regimen 2. PSA at 10 years estimated a probability of 90%  for regimen 1 to be cost-effective given a willingness to pay of 30000 € /QALY. Significant differences in the baseline HAQ and DAS 28 scores were estimated (p<0.0001, and p=0.002, respectively, Mann Whitney U test), although both groups of patients showed a median baseline high disease activity and disability [regimen 1 vs regimen 2: 1.5 (0.5-2.75) vs. 2.7 (0.375-3) for HAQ, and 5.9 (3.5-8.4) vs. 5.0 (2.9-7.0) for DAS28]. At 12 month, the difference in the HAQ scores persisted (p=0.0004), while there was no difference in the DAS28 (p=0.86).

Conclusion: in longstanding RA, a less intensive regimen of RTX with retreatment at clinical relapse seems to be at least equivalent of the more intensive regimen with retreatment every six months. RTX regimen choice may be oriented by the clinical judgment on the balance between the disease activity and the level of disability, and the evaluation of the irreversible/reversible component ratio in the HAQ score. A similar evaluation in patients with early disease is required.

1. Emery P, et al. Rheumatology (Oxford). 2011;50(12):2223-32.


Disclosure:

L. Quartuccio,
None;

R. Di Bidino,
None;

M. Ruggeri,
None;

D. Biasi,
None;

F. Schiavon,
None;

L. Punzi,
None;

S. Adami,
None;

A. Cicchetti,
None;

S. De Vita,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/cost-effectiveness-analysis-of-two-rituximab-based-therapeutic-regimens-for-longstanding-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology